



ESMO SYMPOSIUM ON SIGNALLING PATHWAYS IN CANCER

Targeting the MAPK pathway: From RAS to MEK

13 – 14 March 2015, Barcelona, Spain

Programme

Friday, 13 March 2015

13:30-13:40 10'	Welcome and Introduction	Chairs: Solange Peters, CH and Giampaolo Tortora, IT
--------------------	--------------------------	--

13:40-14:10	Session 1 Opening Keynote	Chairs: Solange Peters, CH and Giampaolo Tortora, IT
30'	Signalling networks : The Ras-Erk pathway in context	Yossi Yarden, IL

14:10-15:30 80'	Session 2 Basic biology, genetics and mouse models	Chair: Mariano Barbacid, ES
20'	Historical overview: How the knowledge of the Ras-Raf-MEK-Erk pathway has developed over the years	Manuela Baccarini, AT
20'	The genomic landscape of RAS-driven tumours	Aldo Scarpa, IT
20'	Mouse model of Ras-driven lung and pancreatic cancer	Mariano Barbacid, ES
20'	Q&A	

15:30-16:00 Coffee break

16:00-17:40 100'	Session 3 Regulation of signaling pathway and therapeutic targeting	Chair: Richard Marais, UK
20'	BRAF and NRAS signalling in melanoma: Basic biology and clinical exploitation	Richard Marais, UK
20'	Activation of PI3K from RAS	Julian Downward, UK
20'	Synthetic lethality with BRAF/MEK inhibitors	Roderick Beijersbergen, NL
20'	Direct targeting of RAS / small molecules	Udai Banerji, UK
20'	Q&A	

17:45 Welcome reception

Saturday, 14 March 2015

08:30-10:25 115'	Session 4 Therapeutic targeting, mechanisms of resistance and overcoming resistance	Chair: Alberto Bardelli, IT
20'	Vertical targeting the RAF-MEK pathway to delay resistance	Alberto Bardelli, IT
20'	Combining BRAF/MEK inhibitors with immunotherapy	Caroline Robert, FR
20'	The role of MET in resistance	Teresa Troiani, IT
20'	Biomarkers of primary resistance to targeted therapies	Pierre Laurent-Puig, FR
20'	Liquid biopsies to monitor cancer pathways	Carlos Caldas, UK
15'	Q&A	

10:25-10:45 Coffee break

10:45-12:40 115'	Session 5 Clinical therapeutic application in cancer	Chair: Jean-Yves Douillard, FR
25'	Melanoma (BRAF, NRAS)	Caroline Robert, FR
20'	Pancreatic cancer (KRAS)	Manuel Hidalgo, ES
25'	Colorectal cancer (RAS, BRAF)	Jean-Yves Douillard, FR
15'	NSCLC (BRAF)	Solange Peters, CH
15'	NSCLC (KRAS)	Egbert Smit, NL
15'	Q&A	

12:40-13:30 Lunch

13:30-15:05 95'	Session 6 Development of novel drugs targeting the pathway	Chairs: Cristiana Sessa, CH and Giampaolo Tortora, IT
20'	Clinical pharmacology and challenges of targeting the pathway	Jan Schellens, NL
20'	Early phase studies with drugs targeting the pathway	Jordi Rodón, ES
20'	ERK inhibition: is it feasible?	Ahmed Samatar, US
20'	Management of toxicity	Cristiana Sessa, CH
15'	Q&A	

15:05-15:15 10'	Take home messages and close	Chairs: Solange Peters, CH and Giampaolo Tortora, IT
---------------------------	-------------------------------------	---